QUINCE THERAPEUTICS, INC.

Profile

Company Names

QUINCE THERAPEUTICS, INC.
CORTEXYME, INC.

Addresses

611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO, CA 94080

329 OYSTER POINT, SUITE 300, SOUTH SAN FRANCISCO, CA 94080

Phone Numbers

(415) 910-5717
415 279 3644

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY, PHARMACEUTICALS

Year Incorporated:

2012

State Incorporated:

DELAWARE

Total Amount Raised:

$226,194,188.00

Number of Funding Rounds:

5
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
5
2026-05-18 
$114,720,542.00 
$186,422,679.00 
$71,702,137.00 
Equity 
4
2025-06-18 
$11,488,304.00 
$21,896,618.00 
$10,408,314.00 
Equity 
3
2018-05-23 
$84,466,700.00 
$85,566,697.00 
$1,099,997.00 
Equity 
2
2017-02-01 
$7,600,000.00 
$8,000,000.00 
$400,000.00 
Debt 
1
2015-12-22 
$7,918,642.00 
$15,918,641.00 
$7,999,999.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
LUCA 
 
BENATTI 
DIRECTOR
QUINCE THERAPEUTICS, INC.
JUNE 
 
BRAY 
DIRECTOR
QUINCE THERAPEUTICS, INC.
STEPHEN 
 
DOMINY 
DIRECTOR
CORTEXYME, INC.   |  LIGHTHOUSE PHARMACEUTICALS, INC.
STEPHEN 
A. 
DOMINY 
DIRECTOR
CORTEXYME, INC.
KRISTEN 
 
GAFRIC 
EXECUTIVE OFFICER
CORTEXYME, INC.
BRENDAN 
 
HANNAH 
EXECUTIVE OFFICER
QUINCE THERAPEUTICS, INC.
DAVID 
 
LAMOND 
DIRECTOR
LAMOND TOMAHAWK MASTER FUND, L.P.   |  LAMOND TOMAHAWK FUND, L.P.   |  LAMOND CAPITAL 1, LP   |  CORTEXYME, INC.   |  NOVOSTEO INC.   |  QUINCE THERAPEUTICS, INC.
CASEY 
 
LYNCH 
EXECUTIVE OFFICER, DIRECTOR
MCLARENS YOUNG INTERNATIONAL LTD   |  ACP INVESTMENT FUND II, L.P.   |  ACP INVESTMENT FUND II-A, L.P.   |  CORTEXYME, INC.   |  ACP INVESTMENT FUND III-A, L.P.   |  ACP PRIVATE INVESTORS III, L.P.   |  ACP INVESTMENT FUND III, L.P.   |  ACP PRIVATE INVESTORS III-A, L.P.   |  UNDISPUTED BOXING, INC.   |  SYFS INTERMEDIATE HOLDINGS, LLC   |  MW COTTONWOOD INVESTORS, LLC   |  MW ASHLYN PLACE HOLDINGS, LLC   |  MW CW RIVER, LLC   |  ROUNDHOUSE MULTIFAMILY FUND II LP   |  RMF2 SILVERBROOK CO-INVEST LP   |  LIGHTHOUSE PHARMACEUTICALS, INC.
MARGI 
 
MCLOUGHLIN 
DIRECTOR
4D MOLECULAR THERAPEUTICS INC   |  CORTEXYME, INC.   |  QUINCE THERAPEUTICS, INC.
RAJIV 
 
PATNI 
DIRECTOR
QUINCE THERAPEUTICS, INC.
ROGER 
 
QUY 
DIRECTOR
EMSENSE CORP   |  SCIODERM, INC.   |  CORTEXYME, INC.
BRIGETTE 
 
ROBERTS 
EXECUTIVE OFFICER, DIRECTOR
QUINCE THERAPEUTICS, INC.
CHARLES 
 
RYAN 
EXECUTIVE OFFICER
APPLIED DNA SCIENCES INC   |  FASTEN INC   |  TOLOKA GROUP, INC.   |  QUINCE THERAPEUTICS, INC.
UNA 
 
RYAN 
DIRECTOR
IQUUM INC   |  BELL BIOSYSTEMS, INC.   |  BIOARRAY THERAPEUTICS, INC.   |  NATIVIS, INC.   |  ELEMENTAL MACHINES, INC.   |  QUINCE THERAPEUTICS, INC.
CHRISTOPHER 
 
SENNER 
DIRECTOR
QUINCE THERAPEUTICS, INC.
DIRK 
 
THYE 
EXECUTIVE OFFICER, DIRECTOR
CIDARA THERAPEUTICS, INC.   |  GEOM THERAPEUTICS, INC.   |  QUINCE THERAPEUTICS, INC.
ILAN 
 
ZIPKIN 
DIRECTOR
ALVINE PHARMACEUTICALS INC   |  CHIMEROS INC   |  SATORI PHARMACEUTICALS INC   |  CORTEXYME, INC.   |  BIONIZ THERAPEUTICS, INC.   |  VIA NOVA THERAPEUTICS, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2026-06-11
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2026-05-18 
2026-06-11
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2026-05-18 
2025-07-01
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2025-06-18 
2018-05-31
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2018-05-23 
2017-02-14
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Debt 
2017-02-01 
2016-01-05
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2015-12-22 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
LIFESCI CAPITAL
000168404
NONE
NONE
CITIZENS JMP SECURITIES, LLC
22208